Has Vijay Ramakrishnan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $127,749 in general payments to Vijay Ramakrishnan, MD across 194 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Vijay Ramakrishnan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Vijay Ramakrishnan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Vijay Ramakrishnan, MD

Otolaryngology · Aurora, CONPI 1619014909

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $78,057 of the $127,749 with a category attached, or 61.1%. 20 manufacturers reported payments, led by Medtronic at 59.9% of the total. 2025 is the largest year on record at $27,043, 4.0 times the $6,747 reported in 2019. Among otolaryngology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$127,749in general payments, 2019–2025

Across 194 payments — averaging $658.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$76K
AstraZeneca$20K
GSK$9K
Optinose US, Inc.$5K
Genentech USA, Inc.$5K
Regeneron$4K
plus $8K from 14 others

$129,971in research payments, 2019–2025

Across 115 payments — averaging $1130.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Optinose US, Inc.$71K
Regeneron$54K
F. Hoffmann-la Roche AG$5K

What the payments were for

Consulting fees$78,05761%
Speaking & faculty fees$32,61726%
Travel & lodging$12,54710%
Food & beverage$4,5294%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	130	$76,473
AstraZeneca	29	$20,362
GSK	8	$8,937
Optinose US, Inc.	1	$5,250
Genentech USA, Inc.	1	$5,245
Regeneron	2	$3,600
Genentech, Inc.	2	$3,443
Novartis	1	$2,220
Eli Lilly	1	$800
Integra Lifesciences Corporation	4	$307
Stryker	2	$178
Sanofi	3	$169
Neurent Medical Limited	1	$127
Medical Device Business Services, Inc.	1	$109
Cook Biotech Incorporated	2	$100
Intersect ENT, Inc.	1	$100
Regeneron Healthcare Solutions, Inc.	1	$99
Aerin Medical Inc.	2	$99
Cook Medical LLC	1	$93
Johnson & Johnson	1	$39

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$127,749 in reported general payments places this provider in the 95th percentile of 174 otolaryngology providers in Colorado.

See all otolaryngology providers in Colorado →

Medicare billing

Part B allowed, 2024

$8,467

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ipratropium Bromide	22	$491
Fluticasone Propionate	18	$217

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Aurora

Andrew WinklerAurora$68K
Ashoke KhanwalkarAurora$28K
Stephen CassAurora$11K
Herman JenkinsAurora$5K
Anne GetzAurora$5K
Todd KingdomAurora$3K
Geoffrey FerrilAurora$3K
Brian CervenkaAurora$3K
Joseph GonzalezAurora$2K
Kimberly NelsonAurora$2K

See the full list for Colorado →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →